Resources|Knowledge Center|Blogs|Chiral Chromatography in Pharmaceutical Applications|

Chiral Chromatography and the Pharmaceutical Industry

Chiral and pharma
Pharmaceutical,Liquid Chromatography

Chiral chromatography and the pharmaceutical industry are closely connected, since chirality describes a molecule’s geometry in three-dimensional space and can change how a drug acts in the body. This is why chirality is important in drug development, a story that runs from Pasteur’s crystals to modern enantioselectivity synthesis and characterization.

Chirality influences research and product development across fields ranging from agriculture to pharmaceutical discoveries and everywhere in between.

What Is Chirality?

Chirality is a specific form of isomerism where a chiral molecule cannot be superimposed on its mirror image, much like a left and a right hand. Its two mirror-image forms are called enantiomers. Enantiomers most commonly arise when a carbon atom carries four different substituents, which makes that atom a chiral center. Read what chiral means in chemistry for further elaboration.

French scientist Louis Pasteur observed in 1848 that a solution of naturally occurring sodium ammonium tartrate rotated a plane of polarized light, but tartrate obtained from chemical synthesis showed no rotation. A closer look showed that the crystals possessed small distinguishable sides. The synthetic sample held crystals that were, from his perspective, half right-handed and half left-handed, while the crystals from the natural sample were all oriented in the same direction. Pasteur concluded that the optical activity of a compound was related to the asymmetric internal arrangement of its molecules. This critical event gave us the first observable evidence of the phenomenon known today as chirality.

Why Chirality Matters in Drug Development

Pasteur’s discovery paved the way for research in medicine as well as chemistry. Many medicines contain chiral active ingredients, including household names such as Advil (ibuprofen). This medication, which many of us reach for when experiencing aches and pains, is actually sold as a racemic mixture, meaning the medication is composed of equal parts right-handed and left-handed molecules.

The two enantiomers of a chiral drug can differ in pharmacological activity, pharmacokinetics, and toxicity. The more pharmacologically active enantiomer is called the eutomer, while the less active enantiomer is called the distomer. These terms are comparative and do not imply that the distomer is necessarily inactive or toxic.

Among the most famous chiral molecules out there, we find not only ibuprofen, but also the Breaking Bad methamphetamine and the maybe less known to the general public (but very well known to any chemistry student) thalidomide that show how far the differences between enantiomers can reach.

dark-gray text-white
Compound
1
1
false
left
top
Eutomer
1
1
false
left
top
Distomer
1
1
false
left
top
Ibuprofen
1
1
false
left
top
S-(+)-ibuprofen (dexibuprofen):
the pharmacologically active
form. It inhibits COX-1 and
COX-2, producing analgesic,
anti-inflammatory, and
antipyretic effects. No
measurable S-to-R inversion
has been reported in humans.
1
1
false
left
top
R-(−)-ibuprofen: has little
direct COX-inhibitory activity.
In humans, approximately 50–
60% undergoes unidirectional
metabolic inversion to S-(+)-
ibuprofen. This is chiral inversion,
not racemization.
1
1
false
left
top
Methamphetamine
1
1
false
left
top
S-(+)-methamphetamine (d
-methamphetamine): the more
potent central nervous system
stimulant, with pronounced
dopaminergic and
noradrenergic effects and high
abuse potential.
1
1
false
left
top
R-(−)-methamphetamine (l-
methamphetamine): a
substantially weaker central
nervous system stimulant at
usual exposure, with
predominantly peripheral
sympathomimetic effects; it
has been used as a nasal
decongestant.
1
1
false
left
top
Thalidomide
1
1
false
left
top
R-(+)-thalidomide: traditionally
described as the eutomer for
sedative activity. However, it
rapidly interconverts with S-
(−)-thalidomide under
physiological conditions, so
the R-enantiomer does not
remain enantiomerically pure
in vivo.
1
1
false
left
top
S-(−)-thalidomide: traditionally
described as the distomer
because it is associated with
teratogenic activity, although
thalidomide pharmacology is
more complex than a strict
eutomer/distomer
assignment. Rapid in vivo
racemization means that
administering either single
enantiomer produces
exposure to both forms.
1
1
false
left
top

Thalidomide became a defining example of why chirality matters in pharmaceutical development: its enantiomers were linked to different biological effects, but they rapidly interconvert in body fluids and tissues. Consequently, isolating the R-enantiomer cannot prevent exposure to the teratogenic S-enantiomer. The resulting birth defects in more than 10,000 children transformed drug-safety regulation. To know more, you can check this 2015 study.

The Regulatory Story: FDA and Single-Enantiomer Drugs

The FDA 1992 Policy Statement for the Development of New Stereoisomeric Drugs required developers to know the stereochemical composition and characterize each enantiomer pharmacologically and toxicologically, and it did not ban racemates. The European Union followed, with guidance on chiral active substances that entered into force in April 1994. That guidance leaves the choice between a racemate and a single enantiomer to the applicant, and it considers the other enantiomer an impurity when only a single enantiomer is selected. Both frameworks made chiral analysis essential for chiral drugs, because developers must characterize enantiomeric purity.

How Chiral HPLC Analysis Supports Pharma

Because scientists and institutions realized that a seemingly subtle difference in structure could have drastically different physiological effects, they needed applications that could distinguish between the two enantiomers of chiral therapeutics. Although many methods of chemical analysis existed, high-performance liquid chromatography (HPLC) excelled at this task due to its simplicity and effectiveness. Liquid chromatography became one of the prevailing methods of analysis for novel chiral pharmaceuticals.

Today, technological advancements allow scientists to separate and quantify individual enantiomers at concentrations appropriate to the method and application. The next logical step was to use chiral separation techniques for processing and manufacturing, and preparative chiral chromatography can also be used to isolate enantiomers at production scale, alongside approaches such as asymmetric synthesis.

The most common direct approach uses a chiral stationary phase (CSP). An indirect approach can use an achiral stationary phase with a chiral selector added to the mobile phase, known as a chiral mobile-phase additive (CMPA).

Advances in chiral stationary phases (CSPs) have expanded selectivity and improved the efficiency of enantiomeric separations. This evolution in processing has been vital to the pharmaceutical industry.  Readers can find the technique itself under chiral HPLC/chiral column chromatography and practical guidance under chiral screening and method development.

How Chiral HPLC Analysis Supports Pharma

Selecting a chiral stationary phase is not always predictable from molecular structure alone. Through PhenoLogix, Phenomenex provides chiral screening support to identify a suitable chiral stationary phase and chromatographic conditions for a specific chiral compound. The Lux family, Phenomenex-coated and immobilized chiral columns, offers complementary amylose- and cellulose-based selectivities and supports screening under normal-phase, reversed-phase, polar-organic, and SFC conditions.

This systematic screening step connects the broader pharmaceutical need to the analytical solution: biological differences require stereochemical characterization, regulatory expectations require each enantiomer to be understood, and reliable chiral HPLC methods depend on identifying suitable stationary phases and chromatographic conditions.

To discuss a chiral screening project, contact your local Phenomenex representative.

How Chiral HPLC Analysis Supports Pharma

Why is chirality important in drug development?

Enantiomers of the same drug can act differently in the body, so one form may help while the other does not or causes harm. Developers need methods that separate enantiomers and measure each one.

Why is chirality important in drug development?

A single-enantiomer drug contains only one enantiomer of a chiral active substance. This differs from a racemate, which contains both.

Why is chirality important in drug development?

No. The FDA 1992 Policy Statement did not ban racemates. It required developers to know the stereochemical composition of the drug.

What happened with thalidomide and chirality?

Thalidomide was sold as a racemate, and the S-enantiomer has been associated with teratogenic activity. Because the enantiomers interconvert in vivo, administering a single enantiomer does not reliably prevent exposure to the other form.